VectorY: Forbion’s next-generation gene therapy play

Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed to fill a gap in diseases where other mAbs and gene therapies have fallen short, beginning with ALS.

Rather than repairing broken or missing genes, VectorY Therapeutics hopes to become a next-generation gene therapy company capable of selectively changing the functionality of intercellular biochemistry, CEO Alexander Vos told BioCentury...